Rhythm Pharmaceuticals Inc
Company Profile
Business description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Contact
222 Berkeley Street
12th Floor
BostonMA02116
USAT: +1 857 264-4280
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
414
Stocks News & Analysis
stocks
6 undervalued US shares that crushed earnings
stocks
Undervalued REIT offers attractive yield post earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 5.60 | 0.06% |
| CAC 40 | 8,532.05 | 47.55 | -0.55% |
| DAX 40 | 26,201.71 | 136.90 | -0.52% |
| Dow JONES (US) | 53,427.77 | 32.01 | -0.06% |
| FTSE 100 | 10,766.89 | 46.59 | 0.43% |
| HKSE | 25,471.15 | 17.92 | 0.07% |
| NASDAQ | 26,313.78 | 331.13 | -1.24% |
| Nikkei 225 | 67,460.73 | 1,759.52 | -2.54% |
| NZX 50 Index | 13,866.18 | 144.20 | 1.05% |
| S&P 500 | 7,704.95 | 40.11 | -0.52% |
| S&P/ASX 200 | 9,070.00 | 5.20 | 0.06% |
| SSE Composite Index | 3,990.30 | 7.65 | 0.19% |